As of 2025-10-15, the Intrinsic Value of Achilles Therapeutics PLC (ACHL) is -8.14 USD. This ACHL valuation is based on the model Peter Lynch Fair Value. With the current market price of 1.48 USD, the upside of Achilles Therapeutics PLC is -649.74%.
Based on its market price of 1.48 USD and our intrinsic valuation, Achilles Therapeutics PLC (ACHL) is overvalued by 649.74%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -8.14 - -8.14 | -8.14 | -649.74% |
| P/E | (56.50) - (71.66) | (65.17) | -4503.4% |
| DDM - Stable | (9.96) - (26.20) | (18.08) | -1321.7% |
| DDM - Multi | (9.27) - (19.33) | (12.57) | -949.2% |
| Market Cap (mil) | 60.83 |
| Beta | 0.91 |
| Outstanding shares (mil) | 41.10 |
| Enterprise Value (mil) | -25.22 |
| Market risk premium | 4.60% |
| Cost of Equity | 12.51% |
| Cost of Debt | 5.00% |
| WACC | 8.75% |